Skin & Cancer Associates Llp

CLIA Laboratory Citation Details

2
Total Citations
5
Total Deficiencyies
4
Unique D-Tags
CMS Certification Number 10D0978532
Address 7800 Sw 87th Ave Ste 300c, Miami, FL, 33173
City Miami
State FL
Zip Code33173
Phone(305) 279-6060

Citation History (2 surveys)

Survey - March 25, 2026

Survey Type: Standard

Survey Event ID: VI6R11

Deficiency Tags: D0000 D5601 D5417

Summary:

Summary Statement of Deficiencies D0000 An announced CLIA recertification survey was conducted at SKIN & CANCER ASSOCIATES LLP from 03/19/2026 to 03/25/2026. The laboratory was surveyed under 42 CFR Part 493 CLIA requirements. Standard deficiencies cited are as follows: D5417 TEST SYSTEMS, EQUIPMENT, INSTRUMENTS, REAGENT CFR(s): 493.1252(d) (d) Reagents, solutions, culture media, control materials, calibration materials, and other supplies must not be used when they have exceeded their expiration date, have deteriorated, or are of substandard quality. This STANDARD is not met as evidenced by: Based on observation, record review and staff interview, the laboratory used an expired Bio SB Mohs Mouse/Rabbit Poly Detector Plus DAD HRP Brown Detection System in (Melanocytic Marker Immunohistochemistry (IHC stain) MART-1 for cryostat sections since November 2025. Findings included: 1-During the laboratory tour on 03/19/2026 at 11:30 AM, the surveyor found that the laboratory had in refrigerator two boxes of Bio SB Mohs mouse/Rabbit Poly Detector Plus DAD HRP Brown: Box#1 in use with lot number 03555 TWJ 24 and expiration date 07/25 and Box#2 not in use with lot number 03550PH045 and expiration date 08/01/2027. 2- Review of Manufacturer Instructions (MI) for the Mohs Mouse /Rabbit Poly Detector Plus DAD HRP Brown Detection System, revealed that in the "Stability "section stated "This product is stable up to the expiration date on the product label. Do not use after expiration date listed on the package label." 3-Patient record review revealed that the laboratory tested two patients with the expired Box#1 in the following dates: P#1 (11/14/2025) and P#2 (01/16/2026). 4-During an Interview on 03/19/2026 at 11:450 AM, the consultant confirmed that the laboratory used the expired kit to test two patients in the dates listed above. Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- D5601 HISTOPATHOLOGY CFR(s): 493.1273(a)(f) (a) As specified in 493.1256(e)(3), fluorescent and immunohistochemical stains must be checked for positive and negative reactivity each time of use. For all other differential or special stains, a control slide of known reactivity must be stained with each patient slide or group of patient slides. Reactions of the control slide with each special stain must be documented. This STANDARD is not met as evidenced by: Based on record review and staff interview, the laboratory failed to have documentation of the acceptability of the positive and negative Quality Control (QC) slides for Melanocytic Marker Immunohistochemical (IHC) stain (MART-1) since 03 /14/2025 and for 6 patients. Findings included: 1-The laboratory used the "Melanoma Quality Control Slides" (MQCS) log to record the acceptability of the daily IHC stain (positive and negative controls). Review of the MQCS log for 2025 revealed that the log was not signed by the Mohs surgeon. There was no record for MCQS log for 2026. 2-Review of "MOHS LOG" for 2025 and 2026 revealed the following testing dates and patients tested with MART-1 IHC stain: 03/14/2025 (one patient), 04/11 /2025 (one patient), 05/23/2025 (one patient), 07/18/2025 (one patient), 11/14/2025 (one patient) and 01/16/2026 (one patient). 3-During an interview on 03/19/2026 at 11: 50 AM the Office Consultant confirmed that the laboratory failed to have records of the acceptability of the positive and negative controls for the staining days that the laboratory used MART-1 stain and that the laboratory tested 6 patients with no documentation of the acceptability of the positive and negative control for MART-1. -- 2 of 2 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - May 17, 2022

Survey Type: Standard

Survey Event ID: ZMM711

Deficiency Tags: D0000 D5217

Summary:

Summary Statement of Deficiencies D0000 A recertification survey conducted on 05/17/2022 found the SKIN AND CANCER ASSOCIATES LLP clinical laboratory not in compliance with 42 CFR Part 493, Requirements for Laboratories. D5217 EVALUATION OF PROFICIENCY TESTING PERFORMANCE CFR(s): 493.1236(c)(1) At least twice annually, the laboratory must verify the accuracy of any test or procedure it performs that is not included in subpart I of this part. This STANDARD is not met as evidenced by: Based on record review and staff interview, the laboratory failed to verify the accuracy of the reading and interpretation of the Hematoxylin and Eosin (H&E) stain at least twice annually in 2020. Findings include: -Review of laboratory peer review records revealed that the laboratory had no documentation for year 2020. -During an interview on 05/17/2022 at 11:30 A.M., the MOHS Consultant confirmed that the laboratory had no documentation of accuracy verification of the reading and interpretation of Hematoxylin and Eosin (H&E) stain at least twice annually in 2020. Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 1 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access